Currently, there are 66.34M common shares owned by the public and among those 64.66M shares have been available to trade.
The company’s stock has a 5-day price change of 1.02% and -15.96% over the past three months. CLDX shares are trading -10.17% year to date (YTD), with the 12-month market performance down to -35.64% lower. It has a 12-month low price of $20.91 and touched a high of $53.18 over the same period. CLDX has an average intraday trading volume of 992.67K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.12%, -8.48%, and -29.71% respectively.
Institutional ownership of Celldex Therapeutics Inc (NASDAQ: CLDX) shares accounts for 109.80% of the company’s 66.34M shares outstanding.
It has a market capitalization of $1.51B and a beta (3y monthly) value of 1.72. The earnings-per-share (ttm) stands at -$2.57. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.15% over the week and 5.18% over the month.
Earnings per share for the fiscal year are expected to increase by 15.23%, and -32.93% over the next financial year. EPS should shrink at an annualized rate of -9.43% over the next five years, compared to 27.41% over the past 5-year period.
Looking at the support for the CLDX, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on February 13, 2025, with the firm’s price target at $44. Citigroup coverage for the Celldex Therapeutics Inc (CLDX) stock in a research note released on October 07, 2024 offered a Buy rating with a price target of $70. Stifel on their part issued Buy rating on June 18, 2024.
